These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21664880)

  • 1. The effect of varenicline on heart rate variability in healthy smokers and nonsmokers.
    Ari H; Celiloğlu N; Ari S; Coşar S; Doganay K; Bozat T
    Auton Neurosci; 2011 Oct; 164(1-2):82-6. PubMed ID: 21664880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of varenicline on Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in healthy smokers and nonsmokers.
    Ari H; Ari S; Coşar S; Celiloğlu N; Aktaş İ; Camci S; Doğanay K; Tütüncü A; Melek M
    Cardiol J; 2015; 22(5):551-6. PubMed ID: 26100824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
    Faessel HM; Smith BJ; Gibbs MA; Gobey JS; Clark DJ; Burstein AH
    J Clin Pharmacol; 2006 Sep; 46(9):991-8. PubMed ID: 16920893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
    Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
    J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers.
    McColl SL; Burstein AH; Reeves KR; Billing CB; Stolar M; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):607-14. PubMed ID: 18288085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.
    Bolliger CT; Issa JS; Posadas-Valay R; Safwat T; Abreu P; Correia EA; Park PW; Chopra P
    Clin Ther; 2011 Apr; 33(4):465-77. PubMed ID: 21635992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
    Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C
    Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varenicline for smoking cessation: a placebo-controlled, randomized study.
    Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
    Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.
    Garza D; Murphy M; Tseng LJ; Riordan HJ; Chatterjee A
    Biol Psychiatry; 2011 Jun; 69(11):1075-82. PubMed ID: 21295286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dopamine type-2 receptor blockade on autonomic modulation.
    Kaya D; Ellidokuz E; Onrat E; Ellidokuz H; Celik A; Kilit C
    Clin Auton Res; 2003 Aug; 13(4):275-80. PubMed ID: 12955552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
    Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
    Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of ipratropium bromide and salbutamol on autonomic heart rate control.
    Kaya D; Barutcu I; Esen AM; Onrat E; Orman A; Unlu M
    Europace; 2004 Nov; 6(6):602-7. PubMed ID: 15519264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational study of safety and efficacy of varenicline for smoking cessation among Filipino smokers.
    Park PW; Casiano EM; Escoto L; Claveria AM
    Curr Med Res Opin; 2011 Oct; 27(10):1869-75. PubMed ID: 21838412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers.
    Burstein AH; Fullerton T; Clark DJ; Faessel HM
    J Clin Pharmacol; 2006 Nov; 46(11):1234-40. PubMed ID: 17050788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers.
    Zhao Q; Schwam E; Fullerton T; O'Gorman M; Burstein AH
    J Clin Pharmacol; 2011 Apr; 51(4):492-501. PubMed ID: 20466870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of orthostatic provocation on the spectral pattern of heart rate variability in healthy subjects].
    Rozentryt P; Trzos G; Strłojewski D; Kozlowski JW; Maciejewski M
    Przegl Lek; 1996; 53(7):534-9. PubMed ID: 8975288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.